Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia
Journal of Thrombosis and Haemostasis · 2024-05 · 22 (5) · 1263-1289
DOI: 10.1016/j.jtha.2023.12.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-05. Verfasst von Glenn F Pierce und 3 weiteren Autor:innen. Beteiligte Einrichtung: World Federation of Hemophilia, Montreal, Quebec, Canada. Electronic address: gpierce@wfh.org. Hauptthemen laut MEDLINE: Dependovirus, Hemophilia A, Genetic Therapy, Liver. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical, Bayer.
Abstract (Originalsprache)
Adeno-associated virus gene therapy has been the subject of intensive investigation for monogenic disease gene addition therapy for more than 25 years, yet few therapies have been approved by regulatory agencies. Most have not progressed beyond phase 1/2 due to toxicity, lack of efficacy, or both. The liver is a natural target for adeno-associated virus since most serotypes have a high degree of tropism for hepatocytes due to cell surface receptors for the virus and the unique liver sinusoidal geometry facilitating high volumes of blood contact with hepatocyte cell surfaces. Recessive monogenic diseases such as hemophilia represent promising targets since the defective proteins are often synthesized in the liver and secreted into the circulation, making them easy to measure, and many do not require precise regulation. Yet, despite initiation of many disease-specific clinical trials, therapeutic windows are often nonexistent, resulting in excess toxicity and insufficient efficacy. Iterative progress built on these attempts is best illustrated by hemophilia, with the first regulatory approvals for factor IX and factor VIII gene therapies eventually achieved 25 years after the first gene therapy studies in humans. Although successful gene transfer may result in the production of sufficient transgenic protein to modify the disease, many emerging questions on durability, predictability, reliability, and variability of response have not been answered. The underlying biology accounting for these heterogeneous responses and the interplay between host and virus is the subject of intense investigation and the subject of this review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- World Federation of Hemophilia, Montreal, Quebec, Canada. Electronic address: gpierce@wfh.org.
- BioMarin Pharmaceutical Inc, Research and Early Development, Novato, California, USA.
- Department of Pediatrics, Indiana University School of Medicine, Wells Center for Pediatric Research, Indiana, USA; Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.
Förderung
- BioMarin Pharmaceutical
- Bayer
Zitieren
APA
Pierce, G. F., Fong, S., Long, B. R., & Kaczmarek, R. (2024). Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia. Journal of Thrombosis and Haemostasis, 22(5), 1263-1289. https://doi.org/10.1016/j.jtha.2023.12.005
Vancouver
Pierce GF, Fong S, Long BR, Kaczmarek R. Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia. Journal of Thrombosis and Haemostasis. 2024;22(5):1263-1289. doi:10.1016/j.jtha.2023.12.005
BibTeX
@article{Pierce2024,
author = {Pierce, Glenn F and Fong, Sylvia and Long, Brian R and Kaczmarek, Radoslaw},
title = {Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
volume = {22},
number = {5},
pages = {1263--1289},
doi = {10.1016/j.jtha.2023.12.005}
}
EUVIMED